Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 program assessing fasedienol in social anxiety disorder

Next Previous
Trial Profile

Phase 3 program assessing fasedienol in social anxiety disorder

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fasedienol (Primary)
  • Indications Social phobia
  • Focus Therapeutic Use
  • Acronyms FEARLESS

Most Recent Events

  • 10 Aug 2023 According to VistaGen Therapeutics media release, company expect to initiate the trial in the second half of calendar 2024 with a study design similar to the registration trials for the three drugs currently approved for the treatment of SAD using the LSAS as the primary efficacy endpoint.
  • 28 Jun 2023 According to VistaGen Therapeutics media release, FEARLESS program in SAD will align with the LSAS-based study design supporting the precedent-setting NDA-enabling programs for the three antidepressants currently approved for treatment of SAD.
  • 07 Apr 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top